Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models

Abstract The EGFR tyrosine kinase inhibitor osimertinib has been approved for the first-line treatment of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) patients. Despite its efficacy, patients develop resistance. Mechanisms of resistance are heterogeneous and not fully understood, and their charac...

Full description

Bibliographic Details
Main Authors: Silvia La Monica, Federica Vacondio, Kamal Eltayeb, Alessio Lodola, Francesco Volta, Martina Viglioli, Francesca Ferlenghi, Francesca Galvani, Maricla Galetti, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Lisa Flammini, Michela Verzè, Roberta Minari, Pier Giorgio Petronini, Marcello Tiseo, Marco Mor, Roberta Alfieri
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-57028-8

Internet

https://doi.org/10.1038/s41598-024-57028-8

Similar Items